Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action.
Level 5 - mechanism / opinion, no new human data
Preclinical bench and animal research without human subjects
PubMed 18285556 · doi:10.2337/db07-1552
What was done
The investigators studied how berberine (BBR) activates AMP-activated protein kinase (AMPK) and tested a derivative, dihydroberberine (dhBBR). AMPK phosphorylation was measured in L6 myotubes and LKB1(-/-) cells with or without the CAMKK inhibitor STO-609. Oxygen consumption was measured in L6 myotubes and isolated muscle mitochondria. Effects of dhBBR on adiposity, tissue triglyceride accumulation, and insulin resistance were evaluated in high-fat-diet-fed rodents.
What was found
The abstract reports no numerical values or confidence intervals. BBR dose-dependently inhibited respiration in L6 myotubes and isolated muscle mitochondria via respiratory complex I inhibition. AMPK activation by BBR occurred independently of LKB1 and CAMKKbeta activity. In high-fat-fed rodents, dhBBR counteracted increases in adiposity, tissue triglyceride accumulation, and insulin resistance with greater in vivo efficacy than BBR.
Why it matters
This study identifies mitochondrial complex I inhibition as the mechanism linking berberine to AMPK activation, similar to metformin. It also highlights dihydroberberine as a potentially more bioavailable derivative for metabolic disease research.
Limits
All findings are derived from cell cultures and rodent models, limiting direct translation to human efficacy and pharmacokinetics. The abstract does not report animal sample sizes, exact dosages, numerical effect sizes, or quantitative bioavailability metrics.
Cited by
- supports Berberine acts as a mitochondrial Complex I inhibitor.